A BSO is performed between the ages of 35 and 40 in BRCA1 carriers and 40 and 45 in BRCA2 carriers due to the late onset and can reduce the risk of ovarian cancer by 96% [123,124,125]. This evidence concerns the gene BRCA2 and ovarian carcinoma.